---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-287065"
form_type: "8-K/A"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-12-31T23:59:59+00:00"
generated_at: "2026-05-28T21:58:45.012812+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma grants COO Sophie Mukadam 300,000 options at $12.00

## Summary
- Sophie Mukadam appointed COO effective Jan 1, 2025; receives 300,000 nonqualified stock options.
- Exercise price $12.00 per share, equal to closing price on grant date Dec 27, 2024.
- Vesting in 16 equal quarterly installments starting Mar 31, 2025, conditioned on continued service.
- Unvested options fully accelerate upon a Change in Control as defined in the Plan.

## SEC filing metadata
- accession: 0001193125-24-287065
- form_type: 8-K/A
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-12-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524287065/0001193125-24-287065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524287065/d905396d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-287065
- JSON: https://secwatch.observer/filing/0001193125-24-287065.json
- Plain text: https://secwatch.observer/filing/0001193125-24-287065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.